MW-150 manufacturers
- MW-150
-
- $97.00
-
2026-06-02
- CAS:1628502-91-9
- Purity: 99.32%
- Supply Ability: 10g
|
| Product Name: | MW-150 | | Synonyms: | MW-150;Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-;inhibit,MW 150,MW150,Autophagy,MW-150,p38 MAPK,Inhibitor;6-(4-Methylpiperazin-1-yl)-3-(naphthalen-2-yl)-4-(pyridin-4-yl)pyridazine;6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine;MW-150, 10 mM in DMSO | | CAS: | 1628502-91-9 | | MF: | C24H23N5 | | MW: | 381.47 | | EINECS: | | | Product Categories: | | | Mol File: | 1628502-91-9.mol |  |
| | MW-150 Chemical Properties |
| Boiling point | 606.1±55.0 °C(Predicted) | | density | 1.202±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 40 mg/mL (104.86 mM; Need ultrasonic) | | form | A solid | | pka | 7.16±0.42(Predicted) | | color | Off-white to light yellow | | InChI | InChI=1S/C24H23N5/c1-28-12-14-29(15-13-28)23-17-22(19-8-10-25-11-9-19)24(27-26-23)21-7-6-18-4-2-3-5-20(18)16-21/h2-11,16-17H,12-15H2,1H3 | | InChIKey | CIIVUDIZZJLXCN-UHFFFAOYSA-N | | SMILES | C1(C2=CC=C3C(=C2)C=CC=C3)=NN=C(N2CCN(C)CC2)C=C1C1C=CN=CC=1 |
| | MW-150 Usage And Synthesis |
| Description | MW-150 (MW01-18-150SRM) is a selective, orally active, neurotransmitter p38α MAPK inhibitor with a Ki of 101 nM. It inhibits the ability of endogenous p38α MAPK to phosphorylate the endogenous substrate MK2 in activated glia. | | Uses | MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1]. | | Biological Activity | MW-150 (MW01-18-150SRM) is a selective, orally active, neurotransmitter p38α MAPK inhibitor with a Ki of 101 nM. It inhibits the ability of endogenous p38α MAPK to phosphorylate the endogenous substrate MK2 in activated glia. | | in vivo | MW-150 (2.5 mg/kg; oral daily for 3-4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests[1].
MW-150 (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APPNLh/NLh × PSP264L/P264L knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice[1]. | Animal Model: | APP/PS1 transgenic (Tg) mouse (overexpresses amyloid-beta)[1] | | Dosage: | 2.5 mg/kg | | Administration: | Oral daily; 3-4 months (until cognitive impairment is present) | | Result: | Improved the Tg mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests. |
| | target | | | IC 50 | p38α: 101 nM (Ki) | | References | [1] Roy SM, et al. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015 Apr 15;6(4):666-80. DOI:10.1021/acschemneuro.5b00002 |
| | MW-150 Preparation Products And Raw materials |
|